Endo Pharmaceuticals (ENDP) Receives Complete Response From FDA On FORTESTA
Tweet Send to a Friend
Endo Pharmaceuticals (Nasdaq: ENDP) received a Complete Response letter from the FDA regarding the New Drug Application for FORTESTA 2 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
